Fed. Circ. Partially Revives AstraZeneca Asthma Drug IP Row
The Federal Circuit on Wednesday reversed a lower court's non-infringement ruling on one patent in an intellectual property dispute over AstraZeneca PLC's Pulmicort Respules pediatric asthma medication but upheld the court's...To view the full article, register now.
Already a subscriber? Click here to view full article